TCGA-A8-A09E-01A-11R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 50
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.510
- MYC_TARGETS_V2+0.500
- E2F_TARGETS+0.440
- MYC_TARGETS_V1+0.440
- OXIDATIVE_PHOSPHORYLATION+0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.380
- FATTY_ACID_METABOLISM+0.350
- PEROXISOME+0.320
- G2M_CHECKPOINT+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.310
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.440
- HEDGEHOG_SIGNALING-0.440
- IL6_JAK_STAT3_SIGNALING-0.430
- TGF_BETA_SIGNALING-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- KRAS_SIGNALING_UP-0.370
- INFLAMMATORY_RESPONSE-0.330
- UV_RESPONSE_DN-0.320
- IL2_STAT5_SIGNALING-0.270
- TNFA_SIGNALING_VIA_NFKB-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 3fca0833-b19b-47af-b75e-c9c45a99373b | — | — | 0.845 |
| 2 | b2b4cc41-5760-4463-bcde-16115ceb12c2 | — | — | 0.830 |
| 3 | TCGA-EW-A1OY-01A-11R-A144-07 | — | B | 0.829 |
| 4 | 9f6a2480-748d-414b-be0b-36be34c24037 | — | — | 0.829 |
| 5 | TCGA-GU-AATQ-01A-11R-A39I-07 | — | — | 0.821 |
| 6 | TCGA-39-5036-01A-01R-1443-07 | — | cohortSQ2 | 0.819 |
| 7 | 81b828aa-cb06-4790-ba3e-efaa39f4eeef | — | — | 0.810 |
| 8 | 2d83a9e6-da2d-47e1-b2e7-4b07b108f7bd | — | — | 0.808 |
| 9 | ee24b470-4509-4687-a91e-6d2b967336b9 | — | — | 0.806 |
| 10 | SRR8518397 | — | E | 0.805 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.380 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| PEROXISOME | 0.320 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.290 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |